[Bisphenol A and breast cancer: State of knowledge and meta-analysis].

Bisphénol A et cancer du sein : état des lieux des connaissances et méta-analyse.
Bisphenol A Bisphénol A Breast cancer Cancer du sein Endocrine disruptors Mechanism Mécanisme Perturbateur endocrinien

Journal

Bulletin du cancer
ISSN: 1769-6917
Titre abrégé: Bull Cancer
Pays: France
ID NLM: 0072416

Informations de publication

Date de publication:
Feb 2023
Historique:
received: 22 03 2022
revised: 02 11 2022
accepted: 18 11 2022
pubmed: 22 12 2022
medline: 18 2 2023
entrez: 21 12 2022
Statut: ppublish

Résumé

Bisphenol A is an endocrine disruptor used in the composition of food containers. It was partially banned in France in 2015 and classified as a "very high-risk substance" in 2017. Bisphenol A's carcinogenic effects have been demonstrated in animal testing. Bisphenol A acts through estrogen-dependent and estrogen-independent pathways. It induces epigenetic changes and impacts the microenvironment of the mammary gland. However, the role of bisphenol A exposure in the development of breast cancer in humans remains controversial. This study documents the current thinking on bisphenol A with an analysis of the mechanisms and a meta-analysis. A literature review and a statistical analysis of linear regression type, with the creation of a Forest plot, were used to perform the meta-analysis of 9 studies including 10,695 patients. Nine case-control studies, published between 1990 and 2021, investigating the association between breast cancer and mean urinary, blood or tissue bisphenol A levels were selected. The meta-analysis did not find a significant association between bisphenol A exposure and the development of breast cancer with an OR=(1 IC95% [0.92-1.08]). This meta-analysis does not show a link between breast cancer and bisphenol A exposure. Nevertheless, the analysis of a pathogenic link between bisphenol A and breast cancer requires additional cohort studies to conclude because of methods of available studies.

Identifiants

pubmed: 36543681
pii: S0007-4551(22)00434-9
doi: 10.1016/j.bulcan.2022.11.011
pii:
doi:

Substances chimiques

Benzhydryl Compounds 0
bisphenol A MLT3645I99
Estrogens 0
Phenols 0

Types de publication

Review Meta-Analysis English Abstract Journal Article

Langues

fre

Sous-ensembles de citation

IM

Pagination

151-159

Informations de copyright

Copyright © 2022 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.

Auteurs

Marie-Bluette Fauconnier (MB)

Institut Curie-Saint-Cloud, département de chirurgie, 35, rue Dailly, 92210 Saint-Cloud, France.

Casilda Albert (C)

Institut Curie-Saint-Cloud, département de chirurgie, 35, rue Dailly, 92210 Saint-Cloud, France.

Ambre Tondreau (A)

Institut Curie-Saint-Cloud, département de chirurgie, 35, rue Dailly, 92210 Saint-Cloud, France.

Louise Maumy (L)

Institut Curie-Saint-Cloud, département de chirurgie, 35, rue Dailly, 92210 Saint-Cloud, France.

Roman Rouzier (R)

Institut François-Baclesse, département de chirurgie, 3, avenue du Général Harris, 14000 Caen, France; Inserm U900, Institut Curie, Saint-Cloud, France.

Claire Bonneau (C)

Institut Curie-Saint-Cloud, département de chirurgie, 35, rue Dailly, 92210 Saint-Cloud, France; Inserm U900, Institut Curie, Saint-Cloud, France. Electronic address: claire.bonneau@curie.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH